11-01 :: December 2010 / January 2011
nanotimes
Companies Facts
death or DNA repair) such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets. Financial details of the agree- ment were not disclosed.
Dr. Henrik Daub, CTO at KINAXO commented: “Posttranslational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action. We are delighted to ap- ply our expertise to support AstraZeneca’s research in such highly promising fields of investigation. This collaboration further strengthens KINAXO’s position as a preferred technology partner for global pharma- ceutical companies.” KINAXO Biotechnologies is a privately-held bio- technology company based in Munich/Martinsried, Germany.
http://www.kinaxo.com
K
opin Corporation (NASDAQ: KOPN) has acquired all of the outstanding common stock
of Scotland-based Forth Dimension Displays Ltd. (FDD), an industry leading provider of all-digital, ultrahigh-resolution, near-to-eye ferroelectric reflec- tive microdisplays. The purchase price was approxi- mately $11 million in cash plus an earnout provision if certain revenue milestones are reached within one year of the purchase date.
“Our acquisition of FDD opens new market oppor- tunities for Kopin and expands our product offe- rings to our customers,” said Kopin President and Chief Executive Officer Dr. John C.C. Fan. “FDD’s ultrahigh-resolution reflective microdisplay is already used extensively within a variety of applications such as high-performance cinematography, training and simulation, 3D metrology and medical imaging. Its
proprietary Time Domain Imaging (TDI™) technology provides beautiful high-resolution, full-color images that are critical for these high-end applications. Kopin is the leading transmissive microdisplay com- pany in the world, and with this acquisition we will be the only microdisplay manufacturer that can offer complete system solutions with either reflective or transmissive liquid crystal display technologies,” Dr. Fan continued. “We are delighted to welcome the company’s employees to the Kopin family.”
FDD had approximately $6 million of revenue in 2010 and Kopin projects that FDD will be accretive to 2011 earnings. All of FDD’s key employees have agreed to join Kopin.
http://www.kopin.com
L
eica Microsystems has effectively matched the Leica TCS SP5 MP multiphoton microscope with
a fully integrated OPO (Optical Parametric Oscillator) solution. The integration of the Coherent Chameleon Compact OPO with the Leica TCS SP5 MP confo- cal and multiphoton microscope allows observation of fast dynamic processes in living cells with deep penetration at high resolution with one integrated microscope system.
Full integration of the OPO within the software control of the multiphoton system greatly facilitates research as it enables the user to precisely adjust the excitation sources as well as all other imaging settings within the same soft ware. This makes the Leica TCS SP5 MP with OPO a powerful tool for in vivo ima- ging.
The Leica TCS SP5 MP with OPO ex tends the choice of excitation wave lengths from formerly up
31
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95